The switching process from buprenorphine sublingual tablets to the monthly buprenorphine subcutaneous depot injection in opioid dependent patients.
buprenorphine
buprenorphine depot injection
extended-release buprenorphine depot
opioid substitution
sublingual buprenorphine
Journal
Addiction biology
ISSN: 1369-1600
Titre abrégé: Addict Biol
Pays: United States
ID NLM: 9604935
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
27
02
2023
received:
16
11
2022
accepted:
20
03
2023
medline:
17
5
2023
pubmed:
15
5
2023
entrez:
15
5
2023
Statut:
ppublish
Résumé
The 2018 European Union (EU) approved weekly and monthly subcutaneous buprenorphine depot injection (BUP-XR), for opioid substitution medication proved to offer some specific treatment benefits. The present study examines the process of switching from buprenorphine sublingual tablets (BUP-SL) to BUP-XR from a patient's point of view. In total, nine patients were surveyed by means of an open-answer questionnaire regarding course and side effects of the medication switch. Six of these patients were surveyed in more detail under BUP-SL, as well as 4 and 16 weeks after the switch to BUP-XR by means of a test battery of questions on socio-demography, withdrawal symptoms, craving, physical well-being, treatment satisfaction and concomitant use of illegal substances. Patients reported significant worse physical well-being and lower treatment satisfaction in 4 weeks compared with 16 weeks after the medication switch to the BUP-XR. Furthermore, they reported significant more frequent co-use of illicit drugs, worse physical well-being, lower treatment satisfaction and more craving experience 4 weeks after the switch compared with the treatment under BUP-SL. Patients 16 weeks under BUP-XR reported significant more illicit co-use and lower treatment satisfaction compared with patients under BUP-SL. Connections between therapy dissatisfaction, physical discomfort, experienced craving and drug co-consumption were discovered. In the first weeks after the medication switch, patients experience potentially distressing symptoms, which, however, seem to diminish over time. Close supervision and comprehensive patient education on possible burdens of the medication switch to the BUP-XR might prevent unfavourable treatment courses and premature therapy dropouts.
Substances chimiques
Buprenorphine
40D3SCR4GZ
Analgesics, Opioid
0
Narcotic Antagonists
0
Tablets
0
Delayed-Action Preparations
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13275Informations de copyright
© 2023 The Authors. Addiction Biology published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.
Références
European Monitoring Centre for Drugs and Drug Addiction. European drug report 2017: trends and development. Publications Office of the European Union; 2017. Accessed March 23, 2018. http://www.emcdda.europa.eu/system/files/publications/4541/TDAT17001ENN.pdf
Mattick RP, Breen C, Kimber J, Davoli M, Breen R. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. In: The Cochrane Collaboration, ed. Cochrane database of systematic reviews. John Wiley & Sons, Ltd; 2003:CD002209. doi:10.1002/14651858.CD002209
Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. In: Cochrane Drugs and Alcohol Group, ed. Cochrane database of systematic reviews. Published online February 6; 2014. doi:10.1002/14651858.CD002207.pub4
Kimber J, Larney S, Hickman M, Randall D, Degenhardt L. Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study. Lancet Psychiatry. 2015;2(10):901-908. doi:10.1016/S2215-0366(15)00366-1
Lugoboni F, Zamboni L, Cibin M, Tamburin S. Intravenous misuse of methadone, buprenorphine and buprenorphine-naloxone in patients under opioid maintenance treatment: a cross-sectional multicentre study. Eur Addict Res. 2019;25(1):10-19. doi:10.1159/000496112
Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and geographic patterns in drug and synthetic opioid overdose deaths-United States, 2013-2019. MMWR Morb Mortal Wkly Rep. 2021;70(6):202-207. doi:10.15585/mmwr.mm7006a4
Goldman B. The news on the street: prescription drugs on the black market. Can Med Assoc. 1998;159:149-150.
Grzybowski S. The black market in prescription drugs. Lancet. 2004;364:28-29. doi:10.1016/S0140-6736(04)17630-7
Schwartz RP, Gryczynski J, O'Grady KE, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. Am J Public Health. 2013;103(5):917-922. doi:10.2105/AJPH.2012.301049
National Institute on Drug Abuse. (2022). Overdose death rates. https://nida.nih.gov/drug-topics/trends-statistics/overdose-death-rates
Centre for Addiction and Mental Health (CAMH). Buprenorphine: buprenorphine is an opioid medication used to treat pain and opioid addiction. 2016. Accessed April 26, 2022. https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/buprenorphine
Vorspan F, Hjelmström P, Simon N, et al. What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine. Expert Opin Drug Deliv. 2019;16(9):907-914. doi:10.1080/17425247.2019.1649252
Dahan A. Opioid-induced respiratory effects: new data on buprenorphine. Palliat Med. 2006;20(Suppl 1):s3-s8. doi:10.1191/0269216306pm1126oa
Walsh S. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend. 2003;70(2):S13-S27. doi:10.1016/S0376-8716(03)00056-5
Karp JF, Butters MA, Begley AE, et al. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry. 2014;75(8):e785-e793. doi:10.4088/JCP.13m08725
Guillery SPE, Hellweg R, Kronenberg G, Bohr U, Kunte H, Enge S. Quality of life in opioid replacement therapy: a naturalistic cross-sectional comparison of methadone/Levomethadone, buprenorphine, and diamorphine patients. Eur Addict Res Published online March 30. 2021;27(5):1-10. doi:10.1159/000514192
European Medicines Agency. Buvidal (buprenorphine): an overview of Buvidal and why it is authorised in the EU. 2018. https://www.ema.europa.eu/en/documents/overview/buvidal-epar-medicine-overview_en.pdf
Chappuy M, Trojak B, Nubukpo P, et al. Prolonged-release buprenorphine formulations: perspectives for clinical practice. Therapies. 2020;75(5):397-406. doi:10.1016/j.therap.2020.05.007
Haight BR, Learned SM, Laffont CM, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2019;393(10173):778-790. doi:10.1016/S0140-6736(18)32259-1
Strang J, Volkow ND, Degenhardt L, et al. Opioid use disorder. Nat Rev Dis Primers. 2020;6(1):3. doi:10.1038/s41572-019-0137-5
Chappuy M, Meroueh F, Trojak B, et al. Factors of interest in extended-release buprenorphine: comparisons between incarcerated and non-incarcerated patients with opioid use disorder. PPA. 2021;15:1259-1267. doi:10.2147/PPA.S311674
Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13(3):293-308. doi:10.3109/00952998709001515
Frank R (Ed). Therapieziel Wohlbefinden. Springer; 2011. doi:10.1007/978-3-642-13760-0
Somoza E, Dyrenforth S, Goldsmith J, Mezinskis J. In search of a universal drug craving scale. Published online 1995.
Guillery SPE, Hellweg R, Enge S, Bohr U, Kunte H, Kronenberg G. Patients' perceptions of opioid replacement therapy: a comparison of diamorphine and methadone/Levomethadone. Int J Ment Health Addiction. 2021;19(6):2194-2203. doi:10.1007/s11469-020-00313-0
Lee JD, McDonald R, Grossman E, et al. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial: extended-release naltrexone at jail release. Addiction. 2015;110(6):1008-1014. doi:10.1111/add.12894
Rice ME, Harris GT. Comparing effect sizes in follow-up studies: ROC area, Cohen's d, and r. Law Hum Behav. 2005;29(5):615-620. doi:10.1007/s10979-005-6832-7
Alcohol and Drug Foundation. Buprenorphine - long acting injectable. Published November 26, 2021. Accessed October 27, 2022. https://adf.org.au/drug-facts/buprenorphine-long-acting-injectable/
MAYO CLINIC. Drugs and supplements buprenorphine (transdermal route). Published May 1, 2022. Accessed May 12, 2022. https://www.mayoclinic.org/drugs-supplements/buprenorphine-transdermal-route/side-effects/drg-20074363
Lofwall MR, Walsh SL, Nunes EV, et al. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial. JAMA Intern Med. 2018;178(6):764-773. doi:10.1001/jamainternmed.2018.1052
Albayaty M, Linden M, Olsson H, Johnsson M, Strandgården K, Tiberg F. Pharmacokinetic evaluation of once-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: an open-label phase 1 study. Adv Ther. 2017;34(2):560-575. doi:10.1007/s12325-016-0472-9
Lintzeris N, Dunlop AJ, Haber PS, et al. Patient-reported outcomes of treatment of opioid dependence with weekly and monthly subcutaneous depot vs daily sublingual buprenorphine: a randomized clinical trial. JAMA Netw Open. 2021;4(5):e219041. doi:10.1001/jamanetworkopen.2021.9041
Gowing L, Farrell M, Bornemann R, Ali R. Substitution treatment of injecting opioid users for preventing transmission of HIV infection. In: The Cochrane Collaboration, ed. Cochrane database of systematic reviews. John Wiley & Sons, Ltd; 2003:CD004145. doi:10.1002/14651858.CD004145
Paliwal P, Hyman SM, Sinha R. Craving predicts time to cocaine relapse: further validation of the now and brief versions of the cocaine craving questionnaire. Drug Alcohol Depend. 2008;93(3):252-259. doi:10.1016/j.drugalcdep.2007.10.002
Addiction Resource. (2021). Switching from methadone to Subutex: benefits and risks. https://www.addictionresource.net/mat/buprenorphine/subutex/switching-from-methadone/
Lintzeris N, Monds LA, Rivas C, et al. Transferring patients from methadone to buprenorphine: the feasibility and evaluation of practice guidelines. J Addict Med. 2018;12(3):234-240. doi:10.1097/ADM.0000000000000396
Kelly SM, O'Grady KE, Brown BS, Mitchell SG, Schwartz RP. The role of patient satisfaction in methadone treatment. Am J Drug Alcohol Abuse. 2010;36(3):150-154. doi:10.3109/00952991003736371
Kelly SM, O'Grady KE, Mitchell SG, Brown BS, Schwartz RP. Predictors of methadone treatment retention from a multi-site study: a survival analysis. Drug Alcohol Depend. 2011;117(2-3):170-175. doi:10.1016/j.drugalcdep.2011.01.008
Zhang L, Zou X, Zhang D, Li X, Zhao P, Ling L. Investigation of repeat client drop-out and re-enrolment cycles in fourteen methadone maintenance treatment clinics in Guangdong, China. Fischer G, ed. PLoS ONE. 2015;10(10):e0139942. 10.1371/journal.pone.0139942
Johnson B, Flensburg OL, Capusan AJ. Patient perspectives on depot buprenorphine treatment for opioid addiction-a qualitative interview study. Subst Abuse Treat Prev Policy. 2022;17(1):40. doi:10.1186/s13011-022-00474-2
Pates RM, McBride AJ, Ball N, Arnold K. Towards an holistic understanding of injecting drug use: an overview of needle fixation. Addict Res Theory. 2001;9(1):3-17. doi:10.3109/16066350109141769
McBride AJ, Pates RM, Arnold K, Ball N. Needle fixation, the drug user's perspective: a qualitative study. Addiction. 2001;96(7):1049-1058. doi:10.1046/j.1360-0443.2001.967104914.x
Mcelrath K. Booting and flushing: needle rituals and risk for bloodborne viruses. J Subst Use. 2006;11(3):177-189. doi:10.1080/14659890600594070
Neale J, Tompkins CNE, Strang J. Prolonged-release opioid agonist therapy: qualitative study exploring patients' views of 1-week, 1-month, and 6-month buprenorphine formulations. Harm Reduct J. 2019;16(1):25. doi:10.1186/s12954-019-0296-4
Usach I, Martinez R, Festini T, Peris JE. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther. 2019;36(11):2986-2996. doi:10.1007/s12325-019-01101-6
Szent-Ivanyi T. Um Arztpraxen zu entlasten: Drogenbeauftragte will mehr Methadon ausgeben. Published March 23, 2020. Accessed October 27, 2022. https://www.rnd.de/politik/corona-und-suchtkranke-mehr-methadon-um-arztpraxen-zu-entlasten-BIVOC7FYKFGIHLVW2N424UN33Y.html
Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2021;26(1):30-39. doi:10.1038/s41380-020-00880-7
Tompkins CNE, Neale J, Strang J. Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder. J Subst Abuse Treat. 2019;104:64-71. doi:10.1016/j.jsat.2019.06.007
Matheson C, Foster R, Schofield J, Browne T. Long-acting depot buprenorphine in people who are homeless: views and experiences. J Subst Abuse Treat. 2022;139:108781. doi:10.1016/j.jsat.2022.108781
Ong AD, Weiss DJ. The impact of anonymity on responses to sensitive Questions1. J Appl Social Pyschol. 2000;30(8):1691-1708. doi:10.1111/j.1559-1816.2000.tb02462.x
Pérez de los Cobos J, Trujols J, Valderrama JC, Valero S, Puig T. Patient perspectives on methadone maintenance treatment in the Valencia region: dose adjustment, participation in dosage regulation, and satisfaction with treatment. Drug Alcohol Depend. 2005;79(3):405-412. doi:10.1016/j.drugalcdep.2005.03.021